Letter
Oncology
Andrea G. S. Pepper, Antonella Zucchetto, Kevin Norris, Erika Tissino, Jerry Polesel, Zarni Soe, David Allsup, Anna Hockaday, Pei Loo Ow, Peter Hillmen, Andrew Rawstron, Daniel Catovsky, Pietro Bulian, Riccardo Bomben, Duncan M. Baird, Christopher D. Fegan, Valter Gattei, Chris Pepper
Article
Biochemistry & Molecular Biology
Elisabetta Melloni, Elena Marchesi, Lorenzo Preti, Fabio Casciano, Erika Rimondi, Arianna Romani, Paola Secchiero, Maria Luisa Navacchia, Daniela Perrone
Summary: Chenodeoxycholic acid and ursodeoxycholic acid were conjugated with paclitaxel to improve its ability to enter cancer cells, while exhibiting lower toxicity on healthy cells.
Review
Environmental Sciences
Simona Pisanti, Erika Rimondi, Elena Pozza, Elisabetta Melloni, Enrico Zauli, Maurizio Bifulco, Rosanna Martinelli, Annalisa Marcuzzi
Summary: Cholesterol biosynthesis is a crucial metabolic pathway for cellular homeostasis, and defects in prenylation play a key role in promoting inflammation activation and mitochondrial dysfunction.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2022)
Letter
Hematology
Mario Tiribelli, Eleonora Toffoletti, Sara Di Giusto, Renato Fanin, Daniela Damiani
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Review
Oncology
Daniela Damiani, Mario Tiribelli
Summary: Despite advances in understanding the biological mechanisms of AML, the prognosis remains poor. The bone marrow microenvironment and immune system play important roles in AML cell persistence and can be targeted for novel therapies. Potential immune-based treatments include monoclonal antibodies, immune checkpoint inhibitors, and cellular therapies. However, identifying optimal targets on leukemic stem cells remains a challenge, impacting the results of ongoing clinical trials.
Article
Biochemistry & Molecular Biology
Domenico Sergi, Enrico Zauli, Fabio Casciano, Paola Secchiero, Giorgio Zauli, Matteo Fields, Elisabetta Melloni
Summary: Hyperglycaemia and increased circulating saturated fatty acids are key metabolic features of type 2 diabetes mellitus that contribute to diabetic retinopathy pathogenesis. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can partially attenuate palmitic acid-induced lipotoxicity in an in vitro model of human retinal pigment epithelium, but further investigation is needed to determine its therapeutic potential for the treatment of diabetic retinopathy.
Article
Oncology
Francesca Palandri, Massimo Breccia, Camilla Mazzoni, Giuseppe Auteri, Elena Maria Elli, Malgorzata M. M. Trawinska, Nicola Polverelli, Mario Tiribelli, Giulia Benevolo, Alessandra Iurlo, Alessia Tieghi, Florian H. H. Heidel, Giovanni Caocci, Eloise Beggiato, Gianni Binotto, Francesco Cavazzini, Maurizio Miglino, Costanza Bosi, Monica Crugnola, Monica Bocchia, Bruno Martino, Novella Pugliese, Mattia Biondo, Marta Venturi, Luigi Scaffidi, Alessandro Isidori, Daniele Cattaneo, Mauro Krampera, Fabrizio Pane, Daniela Cilloni, Gianpietro Semenzato, Roberto M. M. Lemoli, Antonio Cuneo, Elisabetta Abruzzese, Daniela Bartoletti, Simona Paglia, Nicola Vianelli, Michele Cavo, Massimiliano Bonifacio, Giuseppe A. A. Palumbo
Summary: This study explored the prognostic factors of cytopenic myelofibrosis (MF) and found that high molecular risk mutations, intermediate 2/high Dynamic International Prognostic Score System, and intermediate 2/high Myelofibrosis Secondary to Polycythemia Vera and Essential Thrombocythemia Prognostic Model were associated with cytopenic MF. Patients with cytopenia received lower doses of ruxolitinib and had worse treatment outcomes, suggesting the need for alternative therapeutic strategies.
Article
Oncology
Mario Tiribelli, Roberto Latagliata, Massimo Breccia, Isabella Capodanno, Maria Cristina Miggiano, Francesco Cavazzini, Cristina Bucelli, Immacolata Attolico, Sabrina Leonetti Crescenzi, Sabina Russo, Mario Annunziata, Federica Sora, Massimiliano Bonifacio, Olga Mulas, Giuseppina Loglisci, Alessandro Maggi, Gianni Binotto, Elena Crisa, Anna Rita Scortechini, Anna Paola Leporace, Rosaria Sancetta, Pamela Murgano, Elisabetta Abruzzese, Fabio Stagno, Davide Rapezzi, Debora Luzi, Iolanda Vincelli, Monica Bocchia, Carmen Fava, Alessandra Malato, Monica Crugnola, Michele Pizzuti, Francesca Lunghi, Sara Galimberti, Matteo Dalmazzo, Renato Fanin, Emilia Scalzulli, Robin Foa, Alessandra Iurlo, Giuseppe Saglio, Giorgina Specchia
Summary: This study analyzed the use of frontline TKI therapy in Italian patients with CP-CML and found that 55% of patients chose imatinib as their first-line treatment, while second-generation TKIs were predominantly used in younger patients and those without comorbidities.
Review
Biochemistry & Molecular Biology
Daniela Damiani, Mario Tiribelli
Summary: The prognosis of acute myeloid leukemia (AML) remains unsatisfactory due to poor response to therapy or relapse, which can be attributed to the over-expression of multidrug resistance (MDR) proteins. ABCG2, an efflux transporter responsible for inducing MDR in leukemic cells, has the ability to extrude many antineoplastic drugs, leading to AML resistance and/or relapse. This review focuses on the expression and role of ABCG2, as well as its regulation and potential inhibition to counteract drug resistance and improve outcomes in AML patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Matteo Fields, Annalisa Marcuzzi, Arianna Gonelli, Claudio Celeghini, Natalia Maximova, Erika Rimondi
Summary: Neurodegenerative diseases are characterized by progressive loss of neuronal functions and structures. Mitochondrial dysfunction and oxidative stress have been identified as common mechanisms leading to neurodegeneration. Antioxidant therapies, specifically targeting mitochondria, have become increasingly important in reverting neuronal damage. Novel mitochondria-targeted antioxidant compounds, such as MitoQ, SkQ1, MitoVitE and MitoTEMPO, have been developed and studied to address the need for effective treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Nutrition & Dietetics
Elisabetta Melloni, Silvia Grassilli, Arianna Romani, Erika Rimondi, Annalisa Marcuzzi, Enrico Zauli, Paola Secchiero, Guglielmo Paganetto, Alessandra Guerrini, Gianni Sacchetti, Massimo Tacchini
Summary: Convolvulus pluricaulis is a commonly used Indian herb in Ayurvedic medicine known for its neuroprotective and neuroinflammatory action. Recent studies have shown its involvement in lipidic and glucidic metabolism, particularly in the control of hyperlipidaemia and diabetic conditions. It has been found to promote adipocyte differentiation and regulate glucose metabolism through the modulation of key regulators such as PPAR gamma and GLUT-4. Additionally, it exhibits anti-inflammatory effects by downregulating cytokines associated with insulin resistance and glucose intolerance. These findings suggest that Convolvulus pluricaulis could have potential benefits in glycemia and may be used as an adjunctive treatment for diabetes or for better glucose control.
Review
Biochemistry & Molecular Biology
Daniela Damiani, Mario Tiribelli
Summary: The prognosis of acute myeloid leukemia (AML) is poor due to tumor cell immune escape, which weakens T-cells. Inhibiting immune checkpoints (ICs) through immune checkpoint inhibitors (ICIs) has emerged as a promising therapeutic strategy for AML. However, the results of clinical trials testing ICIs, alone or in combination with other treatments, in AML are conflicting.
Editorial Material
Oncology
Erika Tissino, Riccardo Bomben, Valter Gattei, Antonella Zucchetto
Summary: CD49d, the alpha chain of VLA-4 integrin, has a negative impact in CLL patients treated with BTK inhibitors. Evaluating CD49d expression can improve prognostic stratification.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Francesca Palandri, Elena Rossi, Giuseppe Auteri, Massimo Breccia, Simona Paglia, Giulia Benevolo, Elena M. Elli, Francesco Cavazzini, Gianni Binotto, Alessia Tieghi, Mario Tiribelli, Florian H. Heidel, Massimiliano Bonifacio, Novella Pugliese, Giovanni Caocci, Monica Crugnola, Francesco Mendicino, Alessandra D'Addio, Simona Tomassetti, Bruno Martino, Nicola Polverelli, Sara Ceglie, Camilla Mazzoni, Rikard Mullai, Alessia Ripamonti, Bruno Garibaldi, Fabrizio Pane, Antonio Cuneo, Mauro Krampera, Gianpietro Semenzato, Roberto M. Lemoli, Nicola Vianelli, Giuseppe A. Palumbo, Alessandro Andriani, Michele Cavo, Roberto Latagliata, Valerio De Stefano
Summary: The prognostic relevance of complete response to hydroxyurea, predictors of response, and patients' triggers for switching to ruxolitinib in polycythemia vera are uncertain. Many PV patients receive underdosed hydroxyurea, leading to lower response and toxicity rates. Splenomegaly and other symptoms are the main drivers for early switch to ruxolitinib despite poor response to hydroxyurea.
Article
Oncology
Francesca Palandri, Giuseppe A. Palumbo, Massimiliano Bonifacio, Elena M. Elli, Mario Tiribelli, Giuseppe Auteri, Malgorzata M. Trawinska, Nicola Polverelli, Giulia Benevolo, Alessia Tieghi, Fabrizio Cavalca, Giovanni Caocci, Eloise Beggiato, Gianni Binotto, Francesco Cavazzini, Maurizio Miglino, Costanza Bosi, Monica Crugnola, Monica Bocchia, Bruno Martino, Novella Pugliese, Marta Venturi, Alessandro Isidori, Daniele Cattaneo, Mauro Krampera, Fabrizio Pane, Daniela Cilloni, Gianpietro Semenzato, Roberto M. Lemoli, Antonio Cuneo, Elisabetta Abruzzese, Filippo Branzanti, Nicola Vianelli, Michele Cavo, Florian Heidel, Alessandra Iurlo, Massimo Breccia
Summary: Predictors of early discontinuation of ruxolitinib therapy and death on therapy were investigated in patients with myelofibrosis. Low platelet and hemoglobin levels, primary myelofibrosis, no spleen response at 3 months, and low starting dose of ruxolitinib were associated with a higher probability of therapy failure. A predictive model was built to identify patients at higher risk of failure with ruxolitinib monotherapy, who should consider alternative frontline strategies.
